This Plain Language Summary Publication from Future Oncology describes the results from a study which describes how effective a medication called Afatinib is in people who have non-small-cell-lung cancer (NSCLC) caused by unusual mutations.
Read the full article here.
The original article on which this plain language summary is based is titled ‘Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief Report’ and was published in Frontiers in Oncology. Read the original article here.